Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rothenberg

Showing results (121-130 of 162) with videos related to

Pageof 17
Sort By:
American Journal of Clinical Oncology|December 1, 1994
A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colonJ R Eckardt, E Campbell, H A Burris, et al.
American Journal of Clinical Oncology|April 8, 2006
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancerAlbert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Phase I and pharmacokinetic trial of weekly CPT-11M L Rothenberg, J G Kuhn, H A Burris, et al.
Biopharmaceutics & Drug Disposition|May 1, 1997
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatinW D Figg, M C Christian, R Lush, et al.
The Oncologist|May 27, 2018
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to ActionTomas G Neilan, Mace L Rothenberg, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancerNipun B Merchant, Igor Voskresensky, Christopher M Rogers, et al.
Nature Reviews. Clinical Oncology|October 3, 2018
Accelerating anticancer drug development - opportunities and trade-offsSharyl J Nass, Mace L Rothenberg, Rebecca Pentz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group studyM L Rothenberg, J K Benedetti, J S Macdonald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumorsIgor Puzanov, Wooin Lee, Alice P Chen, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Pageof 17

Showing results (121-130 of 162) with videos related to

Sort By:
Pageof 17
American Journal of Clinical Oncology|December 1, 1994
A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colonJ R Eckardt, E Campbell, H A Burris, et al.
American Journal of Clinical Oncology|April 8, 2006
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancerAlbert Craig Lockhart, Gillian F Cropp, Jordan D Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Phase I and pharmacokinetic trial of weekly CPT-11M L Rothenberg, J G Kuhn, H A Burris, et al.
Biopharmaceutics & Drug Disposition|May 1, 1997
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatinW D Figg, M C Christian, R Lush, et al.
The Oncologist|May 27, 2018
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to ActionTomas G Neilan, Mace L Rothenberg, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancerNipun B Merchant, Igor Voskresensky, Christopher M Rogers, et al.
Nature Reviews. Clinical Oncology|October 3, 2018
Accelerating anticancer drug development - opportunities and trade-offsSharyl J Nass, Mace L Rothenberg, Rebecca Pentz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group studyM L Rothenberg, J K Benedetti, J S Macdonald, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2011
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumorsIgor Puzanov, Wooin Lee, Alice P Chen, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2012
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsJeffrey R Infante, Vicki L Keedy, Suzanne F Jones, et al.
Pageof 17